Anti-VEGF Eye Injections: What to Expect
Understanding Anti-VEGF Therapy
Anti-VEGF therapy targets a protein that drives abnormal blood vessel growth in the eye. Understanding what this protein does, and why blocking it matters, helps explain why this treatment has become the standard of care for several retinal diseases.
VEGF stands for vascular endothelial growth factor, a protein your body produces naturally. In healthy tissue, VEGF helps form new blood vessels when needed. In certain retinal diseases, the eye produces too much VEGF, causing abnormal blood vessels to grow beneath or within the retina. These vessels are fragile and tend to leak blood and fluid, which damages the cells responsible for central vision.
Anti-VEGF medications are biologic drugs, meaning they are made from living cells. Once injected into the eye, they bind to VEGF molecules and prevent them from attaching to blood vessel cells. This reduces leakage from existing vessels, stops new abnormal vessels from forming, and can cause existing abnormal vessels to shrink. In many cases, controlling this process can preserve vision and, for some patients, improve it.
Anti-VEGF therapy is used for several retinal conditions where excess VEGF plays a central role. The most common include:
- Wet age-related macular degeneration (wet AMD), in which abnormal blood vessels grow under the macula, the part of the retina responsible for sharp central vision
- Diabetic macular edema (DME), which involves swelling in the central retina caused by diabetes
- Diabetic retinopathy, where diabetes damages blood vessels throughout the retina
- Retinal vein occlusions (RVO), which occur when a vein in the retina becomes blocked and fluid builds up
Before anti-VEGF drugs became available, treatment options for conditions like wet AMD were limited. Laser treatments could slow vision loss but rarely improved sight. Anti-VEGF therapy changed that by allowing retina specialists to stop the disease process and often help patients regain some of the vision they had lost. Today, these injections are the standard of care for multiple serious retinal diseases.
Anti-VEGF Medications Available Today
Several anti-VEGF drugs are currently used to treat retinal disease. They share a common goal but differ in how they work, how often they are given, and which conditions they are approved to treat. Our retina specialists, Dr. Gaurav Gupta and Dr. Pranjal Thakuria, will recommend the medication that is best suited to your specific condition and treatment history.
Lucentis, known generically as ranibizumab, was the first anti-VEGF drug approved specifically for eye use. It is approved for wet AMD, DME, diabetic retinopathy, and retinal vein occlusions, and is typically given every four weeks, though some patients may transition to an extended schedule over time. Biosimilar versions of ranibizumab, including Byooviz and Cimerli, are also available and have the same active ingredient.
Eylea, known generically as aflibercept, is approved for wet AMD, DME, diabetic retinopathy, and retinal vein occlusions. After initial monthly loading doses, it is typically given every four to eight weeks. Eylea HD is a higher-dose formulation of the same drug that may allow longer intervals between injections after the loading phase, reducing the number of visits needed each year for some patients.
Avastin, known generically as bevacizumab, is FDA-approved for certain cancers but is widely used off-label for retinal conditions, meaning it is not FDA-approved specifically for use in the eye. Despite this, large clinical studies have shown it to be effective for wet AMD and other retinal diseases. Many retina specialists use it because of its well-established track record in research, and it is typically given every four to six weeks.
Vabysmo, known generically as faricimab, works differently from other anti-VEGF drugs. It is a bispecific antibody, meaning it blocks two proteins involved in retinal disease: VEGF and angiopoietin-2 (Ang-2). This dual action may provide more complete disease control for some patients. Vabysmo is approved for wet AMD and DME, and some patients may go up to sixteen weeks between injections, which can meaningfully reduce the number of office visits required each year.
Beovu, known generically as brolucizumab, is approved for wet AMD and can be given every eight to twelve weeks after loading doses. However, it carries a known risk of retinal vasculitis, which is inflammation of the blood vessels in the retina, and retinal artery occlusion, which is a blockage of blood flow in the retina. Because of these risks, it is typically reserved for patients who have not responded well to other options. Patients receiving Beovu require close monitoring for signs of inflammation.
Who May Need Anti-VEGF Treatment
Certain health conditions, family history, and lifestyle factors increase the risk of developing retinal diseases that may require anti-VEGF therapy. Knowing your risk factors helps you stay proactive about your eye health.
Advanced age is the primary risk factor for wet AMD, the most common condition treated with anti-VEGF injections. Risk increases significantly after age 60. Having a close relative with AMD also raises a person's likelihood of developing the condition. People with a family history of AMD should discuss screening with their eye care provider.
Diabetes is the leading cause of diabetic retinopathy and diabetic macular edema. The longer a person has diabetes and the less controlled their blood sugar, the greater the risk to their retinal health. High blood pressure and cardiovascular disease also contribute to retinal vascular problems, including retinal vein occlusions. Managing these systemic conditions is an important part of protecting your eyes.
Smoking is one of the most significant modifiable risk factors for AMD and can substantially increase the risk of developing the disease. Quitting smoking at any age can help reduce this risk. A diet rich in leafy greens, fish, and antioxidants may support retinal health, though healthy habits alone cannot replace medical treatment once a condition has developed.
Warning Signs to Watch For
Retinal conditions can develop gradually or appear without warning. Knowing what symptoms to look for helps you seek care at the right time, which can make a meaningful difference in your outcome.
Many retinal conditions develop slowly. Early signs may include blurred central vision, difficulty reading, and a need for brighter light. Straight lines may appear wavy or distorted, a symptom called metamorphopsia. These changes are often subtle at first and may only affect one eye, making them easy to dismiss or overlook.
Some retinal conditions cause sudden symptoms that require immediate attention. A rapid increase in floaters, flashes of light, a shadow spreading across your vision, or a sudden loss of vision in one eye are serious warning signs. If you experience any of these, see a retina specialist or go to the emergency room right away. Delaying care can lead to severe and potentially irreversible vision loss.
Diagnosis and Testing
Before treatment begins, our retina specialists use several diagnostic tools to examine the retina in detail, confirm the diagnosis, and plan the most appropriate course of care. These tests are safe, typically quick, and essential for guiding your treatment.
A retina specialist will begin with a comprehensive dilated eye exam. Eye drops are used to widen the pupil, allowing a detailed view of the retina. This exam can reveal abnormal blood vessels, fluid buildup, bleeding, and other signs of retinal disease. Visual acuity testing is also performed to measure how well you see at various distances.
Optical coherence tomography, or OCT, is a noninvasive imaging test that creates detailed, cross-sectional pictures of the retina. It can detect fluid beneath or within the retinal layers, measure retinal thickness, and reveal structural changes at a microscopic level. OCT is one of the most important tools used to diagnose retinal conditions and to track how well your treatment is working over time.
Fluorescein angiography is an imaging test that uses a special dye to photograph blood flow in the retina. The dye is injected into a vein in the arm and travels to the eye within seconds, after which a camera takes rapid images to identify leaking vessels, areas of poor blood flow, and abnormal vessel growth. This test helps our specialists plan the most targeted and effective treatment approach.
The Injection Procedure
Many patients feel anxious about the idea of an injection in the eye. Understanding what actually happens before, during, and after the procedure can help reduce that anxiety. Most patients find the experience far more comfortable than they anticipated.
The eye is cleaned with an antiseptic solution to minimize infection risk. Numbing drops or a small amount of local anesthetic is applied to reduce discomfort. A small device called a lid speculum may be used to gently hold the eyelids open. This preparation process typically takes just a few minutes.
The injection is performed using a very fine needle inserted through the white part of the eye, called the sclera, into the vitreous cavity, which is the gel-filled space inside the eye. The medication is delivered in a very small volume. Most patients describe the sensation as brief pressure rather than sharp pain. The injection itself takes only a few seconds, and the full office visit, including preparation and a brief check afterward, usually takes about 30 minutes.
Immediately after the injection, you may notice floaters, mild redness on the white of the eye, or a gritty sensation. These effects are normal and usually resolve within a few days. Your retina specialist may check your eye pressure before you leave. Most people can return to normal activities the same day, though you should follow any specific instructions provided by your care team.
Treatment frequency depends on the medication used and how your eye responds. Many patients begin with a series of monthly loading doses, typically three to four injections given four weeks apart. After this initial phase, your retina specialist may extend the interval between injections using a treat-and-extend approach, increasing the time gradually based on your response. With newer agents like Vabysmo and Eylea HD, some patients can go three to four months between injections. Individual needs vary widely and are reassessed at each visit.
What to Expect from Treatment
Anti-VEGF therapy offers meaningful benefits for most patients, but it is important to have realistic expectations. Our retina specialists will discuss your likely outcomes based on your specific condition, how early treatment is starting, and how your eye responds over time.
Anti-VEGF treatment improves vision in a meaningful proportion of patients and stabilizes vision in the large majority of those treated for wet AMD. Results for DME and retinal vein occlusions are similarly encouraging. The primary goal of treatment is to preserve your current vision and, when possible, improve it. Not every patient will experience improvement, but most can expect their condition to stabilize with consistent treatment.
Anti-VEGF therapy requires ongoing commitment. Skipping or delaying injections can allow disease activity to return, leading to new fluid leakage and further vision loss. Some of that vision loss may not be recoverable. Keeping all scheduled appointments is one of the most important things you can do to protect your sight. If barriers make it difficult to attend visits, it is worth discussing those concerns directly with your retina specialist.
Anti-VEGF injections have a strong safety profile, and the vast majority of patients tolerate them well. Common side effects are minor and temporary, including mild redness, floaters, and a gritty or sore feeling that typically resolves in a day or two. Serious complications are rare. Endophthalmitis, a severe infection inside the eye, is uncommon but is a medical emergency. Seek immediate care if you develop severe eye pain, significant vision loss, markedly increased redness, or discharge from the eye within days of receiving an injection.
Living with Long-Term Anti-VEGF Treatment
For most patients, anti-VEGF therapy is a long-term commitment rather than a short-term course. With the right strategies and support in place, many people manage their treatment schedules effectively and maintain a good quality of life.
Using a calendar, setting phone reminders, or asking a family member to help track appointments can make it easier to stay consistent. Some patients find it helpful to coordinate injection visits with other regular errands or appointments. Building a routine around your treatment schedule helps reduce the chance of a missed visit.
Between appointments, you can use an Amsler grid to monitor your vision at home. This is a simple chart with a grid of straight lines and a central dot. By covering one eye and looking at the central dot, you can detect changes such as new distortion, blurriness, or areas that appear missing. These changes may indicate that the disease is becoming more active, and any new findings should be reported to your retina specialist promptly rather than waiting for your next scheduled visit.
Living with a chronic eye condition and undergoing regular injections can be stressful, and it is completely normal to feel anxious or concerned about the future. Talking with family, friends, or a counselor can be genuinely helpful. Low-vision rehabilitation services and patient support groups are also available for those who have experienced significant changes in their vision.
When to See a Retina Specialist
Knowing when to initiate care and when to seek urgent attention during treatment are both critical parts of protecting your vision. Our retina specialists are here to guide you through every stage of this process.
If you have been diagnosed with wet AMD, DME, diabetic retinopathy, or a retinal vein occlusion, your eye care provider may refer you to a retina specialist. Retina specialists are ophthalmologists with additional fellowship training focused on diseases and surgery of the retina. Starting treatment promptly after diagnosis gives you the best opportunity to preserve your vision.
While receiving anti-VEGF injections, certain symptoms require immediate attention. Contact your retina specialist or go to the emergency room right away if you experience severe eye pain, a sudden decrease in vision, significantly increased redness, new flashes of light, a sudden increase in floaters, or a shadow spreading across part of your vision. These could be signs of a serious complication such as endophthalmitis, retinal detachment, or retinal artery occlusion. Early treatment of these complications consistently produces the best outcomes.
Frequently Asked Questions
These answers address common questions our patients ask about anti-VEGF therapy, with guidance to help you make informed decisions about your care.
Most patients are surprised by how little discomfort they feel. The eye is numbed before the injection, and the injection itself takes only a few seconds. Patients commonly describe the sensation as brief pressure rather than sharp pain. Some mild soreness or irritation may occur afterward and usually clears within a day or two. If discomfort feels significant or unusual, let your care team know right away.
For most patients, treatment is ongoing because the underlying diseases, including wet AMD and diabetic eye disease, are chronic conditions that can reactivate if treatment stops. However, as your condition stabilizes, your retina specialist may gradually extend the time between injections. The schedule is regularly reassessed based on your eye's response, and changes are made with the goal of protecting your vision while reducing the burden of frequent visits where possible.
Anti-VEGF therapy significantly reduces the risk of severe vision loss, and the large majority of patients with wet AMD maintain stable vision with consistent treatment. That said, outcomes vary from person to person, and no treatment can ensure a specific result. Patients whose disease was advanced before starting therapy, or who experience gaps in treatment, may be at greater risk of vision loss. Consistent follow-up and staying on schedule provide the strongest protection available.
All FDA-approved anti-VEGF drugs are effective for treating retinal conditions, but they differ in ways that matter for individual patients. They vary in molecular structure, how long they remain active in the eye, dosing intervals, and which conditions each is approved to treat. Vabysmo blocks two disease-driving proteins instead of one, and Eylea HD may allow longer periods between injections. Your retina specialist will recommend the medication that best fits your diagnosis, lifestyle, and treatment history.
For most patients with wet AMD, DME, or retinal vein occlusions, anti-VEGF injections are currently the most effective treatment available. In select cases, laser photocoagulation or steroid implants such as Ozurdex (a dexamethasone implant) may be used as alternatives or as additions to anti-VEGF therapy. Research into longer-lasting approaches, including sustained-release implants and gene therapy, is ongoing. Your retina specialist can explain which options are appropriate for your specific situation.
Do not wait for your next scheduled appointment. New or worsening distortion, blurriness, or any sudden change in vision between visits should be reported to your retina specialist promptly. Using an Amsler grid at home can help you detect subtle changes early. If symptoms appear suddenly or feel severe, such as a rapid loss of vision or a new shadow in your visual field, treat it as an urgent situation and seek care the same day.
Schedule a Consultation at Rhode Island Eye Institute
Our fellowship-trained retina specialists, Dr. Gaurav Gupta and Dr. Pranjal Thakuria, bring deep expertise and genuine dedication to every patient managing a retinal condition. At Rhode Island Eye Institute, you will find advanced diagnostic technology and a full team of subspecialists working together under one roof to provide the highest level of care. Whether you are just beginning your treatment journey or seeking a second opinion, we are here to help you protect your vision and navigate every step of the process with confidence.